Los Angeles Capital Management LLC Buys 9,054 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Los Angeles Capital Management LLC lifted its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 19.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 55,612 shares of the company’s stock after purchasing an additional 9,054 shares during the period. Los Angeles Capital Management LLC’s holdings in Denali Therapeutics were worth $1,141,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Alps Advisors Inc. raised its stake in Denali Therapeutics by 0.8% in the 3rd quarter. Alps Advisors Inc. now owns 101,400 shares of the company’s stock valued at $2,092,000 after acquiring an additional 780 shares during the period. PNC Financial Services Group Inc. grew its holdings in Denali Therapeutics by 48.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock valued at $53,000 after buying an additional 807 shares in the last quarter. CWM LLC grew its holdings in Denali Therapeutics by 216.7% in the 4th quarter. CWM LLC now owns 2,011 shares of the company’s stock valued at $43,000 after buying an additional 1,376 shares in the last quarter. Assetmark Inc. grew its holdings in Denali Therapeutics by 65.3% in the 4th quarter. Assetmark Inc. now owns 3,550 shares of the company’s stock valued at $76,000 after buying an additional 1,402 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Denali Therapeutics by 10.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,787 shares of the company’s stock valued at $489,000 after buying an additional 2,108 shares in the last quarter. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Price Performance

Shares of DNLI opened at $22.63 on Monday. Denali Therapeutics Inc. has a 1 year low of $14.56 and a 1 year high of $31.03. The company has a market capitalization of $3.23 billion, a price-to-earnings ratio of -23.57 and a beta of 1.37. The business has a 50-day moving average of $18.88 and a 200-day moving average of $19.16.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 11.46% and a negative net margin of 36.51%. During the same quarter in the prior year, the business earned ($0.80) earnings per share. As a group, sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.78 EPS for the current year.

Insider Transactions at Denali Therapeutics

In related news, Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $18.29, for a total transaction of $30,471.14. Following the completion of the sale, the director now owns 118,043 shares of the company’s stock, valued at $2,159,006.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $18.29, for a total transaction of $30,471.14. Following the completion of the sale, the director now owns 118,043 shares of the company’s stock, valued at $2,159,006.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steve E. Krognes sold 92,500 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $20.50, for a total value of $1,896,250.00. Following the sale, the director now directly owns 47,341 shares of the company’s stock, valued at approximately $970,490.50. The disclosure for this sale can be found here. Insiders sold 95,624 shares of company stock worth $1,958,403 over the last ninety days. 7.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. The Goldman Sachs Group reduced their target price on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, February 29th. UBS Group reduced their price objective on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, April 9th. HC Wainwright reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Denali Therapeutics in a research note on Wednesday, May 8th. Wedbush reduced their price objective on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 8th. Finally, Stifel Nicolaus reduced their price objective on Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a research note on Wednesday, May 8th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.22.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.